Antigenic Target of Autoantibodies Identified in Inclusion Body Myositis

Identification of autoantibodies and their antigenic target in IBM should aid diagnosis.

Sporadic inclusion body myositis (sIBM) is the most common acquired muscle disease in people older than 50, with an estimated prevalence of 0.5 to 1 case per 100,000 people. IBM is traditionally considered one of the inflammatory myopathies, along with polymyositis (PM) and dermatomyositis (DM). Sporadic IBM is refractory to the immune suppressive treatment that is generally effective for PM and DM. For this reason and because sarcoplasmic and myonuclear protein aggregates accumulate within muscle in sIBM, there has been much debate about whether sIBM is autoimmune in origin or primarily a degenerative disorder of muscle. Now, two investigative groups have individually identified that autoantibodies are directed against cytosolic 5′-nucleot…

Reviewing Author

Michael Benatar, MD, MS, PhD

Disclosures

Grant / Research supportNIH NeuroBioBank; ALS Association; NIH/National Institute of Neurological Disorders and Stroke; NIH/National Center for Advancing Translational Sciences; FDA; Department of Defense

Editorial boardsCochrane Collaboration

Leadership positions in professional societiesMuscle Study Group Executive Committee

Michael Benatar, MD, MS, PhD

Disclosures

Editorial boardsCochrane Collaboration

Leadership positions in professional societiesMuscle Study Group Executive Committee